MOATAZEDI DAVID 4

4 · Evolus, Inc. · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 20, 2026

Evolus (EOLS) CEO David Moatazedi Receives Equity Awards

What Happened

David Moatazedi, President and Chief Executive Officer of Evolus (EOLS), received equity awards on February 17, 2026. The filing shows three grants totaling 1,397,177 award units: 313,212 restricted stock units (RSUs), 626,424 performance-based restricted stock units (PSUs, derivative), and 457,541 option-type awards (derivative). Each grant is reported with a $0 acquisition price (grant award).

Key Details

Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (appears timely).
Grants and reported amounts: 313,212 RSUs (F1); 626,424 PSUs (F2/F3); 457,541 option-style awards (F4). Total = 1,397,177 units.
Reported acquisition price: $0.00 for all grants (standard for reported awards/grants).
Vesting/terms:
- RSUs vest in four equal annual installments beginning Feb 17, 2026, subject to continued service and certain acceleration events (F1).
- PSUs can pay up to 200% of target based on pre-established financial metrics and relative total shareholder return over a three-year performance period ending Dec 31, 2028; any earned PSUs vest after certification (F2/F3).
- Option-style awards vest in four equal annual installments beginning Feb 17, 2026, subject to continued service and certain acceleration events (F4).
Shares owned after transaction: not disclosed in the provided excerpt.
Filing timeliness: filed two days after the transaction date; no late-filing indication in the excerpt.

Context

These are compensation grants (award code A), not open-market purchases or sales—so they reflect executive pay, not a direct market bet by the insider. PSUs are performance-based and may pay out between 0%–200% of target depending on results; they only convert to shares if performance goals are met and certified after the performance period. Vesting schedules and potential acceleration (e.g., on certain terminations or change in control) are noted in the footnotes.

Form 4

Period: 2026-02-17

DirectorSee Remarks

Transactions

Award
Common Stock
[F1]
2026-02-17+313,212→ 667,600 total
Award
Performance Restricted Stock Units
[F2][F3]
2026-02-17+626,424→ 626,424 total
→ Common Stock (626,424 underlying)
Award
Stock Option (Right to Buy)
[F4]
2026-02-17+457,541→ 457,541 total
Exercise: $4.39Exp: 2036-02-17→ Common Stock (457,541 underlying)

Footnotes (4)

[F1]Represents shares issuable upon settlement of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control).
[F2]Each performance-based restricted stock unit (PSU) represents the right to receive, upon vesting, up to 200% of the target number of shares of common stock of the issuer.
[F3]The number of shares issuable upon vesting is based on performance against pre-established financial metrics and relative total shareholder return (TSR) over a three-year performance period ending December 31, 2028. Subject to certification of performance results, any earned PSUs vest following the performance period.
[F4]The shares subject to the option vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control).

Signature

/s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi|2026-02-19

1 file